Profusa (PFSA) Cash from Operations Growth (1y) (2023 - 2026)
Profusa (PFSA) Cash from Operations Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | -12.60% |
| 10 | Profusa | 122,893.68 | -252,106.32 | - | -384.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -384.17% |
| Dec 31, 2025 | -2,055.04% |
| Sep 30, 2025 | -821.43% |
| Jun 30, 2025 | 108.96% |
| Mar 31, 2025 | -91.20% |
| Dec 31, 2024 | 31.06% |
| Sep 30, 2024 | -140.17% |
| Jun 30, 2024 | -44.50% |
| Mar 31, 2024 | 70.94% |
| Dec 31, 2023 | -92.48% |
| Sep 30, 2023 | -344.83% |
| Jun 30, 2023 | -329.44% |
| Mar 31, 2023 | -319.62% |